文献速递白血病

信号突变的克隆干扰可恶化核心结合因子急性髓系白血病的预后

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.
PubMed 文献 · Blood · 2018-04-24

在445例接受强化化疗的核心结合因子急性髓系白血病(CBF AML)成人及儿童患者中,对6个信号基因进行深度测序。152例(34%)无信号克隆,167例(38%)有单个信号克隆,126例(28%)存在多个信号克隆(克隆干扰)。克隆干扰与较差的无事件生存相关(P < 10^-4),而单个信号克隆则不然(P = .44)。

要点

  • 445例CBF AML中,152例(34%)无信号克隆,167例(38%)有单个信号克隆,126例(28%)存在克隆干扰。
  • 克隆干扰与较差的无事件生存相关(P < 10^-4),而单个信号克隆则不然(P = .44)。
  • 克隆干扰不影响完全缓解率或1-2疗程后的微小残留病。

核心结论

  • 信号突变的克隆干扰与较差的无事件生存相关,且独立于临床参数和特定信号克隆的存在。
  • 结果表明特定的克隆架构可预示AML的不同预后。

研究设计与样本

  • 分析445例接受强化化疗的成人及儿童CBF AML患者队列,对6个信号基因(KIT、NRAS、KRAS、FLT3、JAK2、CBL)进行深度测序。
  • 克隆和复发样本的基因分型表明信号突变发生在独立克隆中,定义为克隆干扰(或平行演化)。

主要发现

  • 152例(34%)无信号克隆,167例(38%)有单个信号克隆,126例(28%)存在多个信号克隆(克隆干扰)。
  • 克隆干扰与年龄较大(P = .004)和inv(16)亚型(P = .025)相关,与白细胞计数或染色质/黏连蛋白基因突变无关。
  • 单个克隆或克隆干扰患者的信号突变中位等位基因频率均为31%(P = .14)。
  • KIT、FLT3和NRAS/KRAS变异谱在组间存在差异。
  • 克隆干扰不影响完全缓解率或1-2疗程后的微小残留病,但与较差的无事件生存相关(P < 10^-4),而单个信号克隆则不然(P = .44)。

关键数值与推荐

  • 克隆干扰与较差的无事件生存相关(P < 10^-4),单个信号克隆与无事件生存无显著相关(P = .44)。
  • 克隆干扰与年龄较大(P = .004)和inv(16)亚型(P = .025)相关。
  • 单个克隆或克隆干扰患者的信号突变中位等位基因频率为31%(P = .14)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in receptor tyrosine kinase/RAS signaling pathway genes are frequent in core-binding factor (CBF) acute myeloid leukemias (AMLs), but their prognostic relevance is debated. A subset of CBF AML patients harbors several signaling gene mutations. Genotyping of colonies and of relapse samples indicates that these arise in independent clones, thus defining a process of clonal interference (or parallel evolution). Clonal interference is pervasive in cancers, but the mechanisms underlying this process remain unclear, and its prognostic impact remains unknown. We analyzed a cohort of 445 adult and pediatric patients with CBF AML treated with intensive chemotherapy and with deep sequencing of 6 signaling genes (KIT, NRAS, KRAS, FLT3, JAK2, CBL). A total of 152 (34%), 167 (38%), and 126 (28%) patients harbored no, a single, and multiple signaling clones (clonal interference), respectively. Clonal interference of signaling mutations was associated with older age (P = .004) and inv(16) subtype (P = .025) but not with white blood cell count or mutations in chromatin or cohesin genes. The median allele frequency of signaling mutations was 31% in patients with a single clone or clonal interference (P = .14). The repertoire of KIT, FLT3, and NRAS/KRAS variants differed between groups. Clonal interference did not affect complete remission rate or minimal residual disease after 1-2 courses, but it did convey inferior event-free survival (P < 10-4), whereas the presence of a single signaling clone did not (P = .44). This inferior outcome was independent of clinical parameters and of the presence of specific signaling clones. Our results suggest that specific clonal architectures can herald distinct prognoses in AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Itzykson R, Duployez N, Fasan A, et al. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. Blood. 2018. PMID: 29692343. doi:10.1182/blood-2018-03-837781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。